Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Glucan particles for macrophage targeted delivery of nanoparticles.

Soto ER, Caras AC, Kut LC, Castle MK, Ostroff GR.

J Drug Deliv. 2012;2012:143524. doi: 10.1155/2012/143524. Epub 2011 Oct 13.

2.

Characterization of multilayered nanoparticles encapsulated in yeast cell wall particles for DNA delivery.

Soto ER, Ostroff GR.

Bioconjug Chem. 2008 Apr;19(4):840-8. doi: 10.1021/bc700329p. Epub 2008 Apr 1.

PMID:
18376856
3.

Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.

Chen Y, Bathula SR, Li J, Huang L.

J Biol Chem. 2010 Jul 16;285(29):22639-50. doi: 10.1074/jbc.M110.125906. Epub 2010 May 11.

4.

EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery.

Xie X, Li F, Zhang H, Lu Y, Lian S, Lin H, Gao Y, Jia L.

Eur J Pharm Sci. 2016 Feb 15;83:28-35. doi: 10.1016/j.ejps.2015.12.014. Epub 2015 Dec 9.

PMID:
26690044
5.

Gold nanoparticles with a monolayer of doxorubicin-conjugated amphiphilic block copolymer for tumor-targeted drug delivery.

Prabaharan M, Grailer JJ, Pilla S, Steeber DA, Gong S.

Biomaterials. 2009 Oct;30(30):6065-75. doi: 10.1016/j.biomaterials.2009.07.048. Epub 2009 Aug 12.

PMID:
19674777
6.

Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.

Jiang J, Yang SJ, Wang JC, Yang LJ, Xu ZZ, Yang T, Liu XY, Zhang Q.

Eur J Pharm Biopharm. 2010 Oct;76(2):170-8. doi: 10.1016/j.ejpb.2010.06.011. Epub 2010 Jun 25.

PMID:
20600887
7.

Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery.

Zhang C, Zhao L, Dong Y, Zhang X, Lin J, Chen Z.

Eur J Pharm Biopharm. 2010 Sep;76(1):10-6. doi: 10.1016/j.ejpb.2010.05.005. Epub 2010 May 22.

PMID:
20472060
8.

Surfactant templating effects on the encapsulation of iron oxide nanoparticles within silica microspheres.

Zheng T, Pang J, Tan G, He J, McPherson GL, Lu Y, John VT, Zhan J.

Langmuir. 2007 Apr 24;23(9):5143-7. Epub 2007 Mar 31.

PMID:
17397201
9.

Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein-mediated drug resistance.

Huang IP, Sun SP, Cheng SH, Lee CH, Wu CY, Yang CS, Lo LW, Lai YK.

Mol Cancer Ther. 2011 May;10(5):761-9. doi: 10.1158/1535-7163.MCT-10-0884. Epub 2011 Mar 16.

10.

Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.

Han L, Huang R, Liu S, Huang S, Jiang C.

Mol Pharm. 2010 Dec 6;7(6):2156-65. doi: 10.1021/mp100185f. Epub 2010 Oct 14.

PMID:
20857964
11.

Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux.

Chavanpatil MD, Khdair A, Gerard B, Bachmeier C, Miller DW, Shekhar MP, Panyam J.

Mol Pharm. 2007 Sep-Oct;4(5):730-8. Epub 2007 Aug 18.

PMID:
17705442
12.

Surfactant-polymer nanoparticles: a novel platform for sustained and enhanced cellular delivery of water-soluble molecules.

Chavanpatil MD, Khdair A, Panyam J.

Pharm Res. 2007 Apr;24(4):803-10. Epub 2007 Feb 21.

PMID:
17318416
13.

Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck.

Nan A, Ghandehari H, Hebert C, Siavash H, Nikitakis N, Reynolds M, Sauk JJ.

J Drug Target. 2005 Apr;13(3):189-97.

PMID:
16036307
14.

Macrophage uptake of core-shell nanoparticles surface modified with poly(ethylene glycol).

Zahr AS, Davis CA, Pishko MV.

Langmuir. 2006 Sep 12;22(19):8178-85.

PMID:
16952259
15.

Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin.

Yadav AK, Mishra P, Jain S, Mishra P, Mishra AK, Agrawal GP.

J Drug Target. 2008 Jul;16(6):464-78. doi: 10.1080/10611860802095494 .

PMID:
18604659
16.

Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug.

Beh CW, Seow WY, Wang Y, Zhang Y, Ong ZY, Ee PL, Yang YY.

Biomacromolecules. 2009 Jan 12;10(1):41-8. doi: 10.1021/bm801109g.

PMID:
19072631
17.

A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells.

Wong HL, Rauth AM, Bendayan R, Manias JL, Ramaswamy M, Liu Z, Erhan SZ, Wu XY.

Pharm Res. 2006 Jul;23(7):1574-85. Epub 2006 Jun 24.

PMID:
16786442
18.

Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.

Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A.

Clin Cancer Res. 2000 May;6(5):1949-57.

19.

Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin.

Xiong XB, Lavasanifar A.

ACS Nano. 2011 Jun 28;5(6):5202-13. doi: 10.1021/nn2013707. Epub 2011 Jun 10.

PMID:
21627074
20.

Tumor targeting using anti-her2 immunoliposomes.

Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC.

J Control Release. 2001 Jul 6;74(1-3):95-113.

PMID:
11489487
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk